Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Interferon Beta in RRMS
NCT02364986Phase 1Unknown
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS) (2 arms). Primary endpoint: Change of mRNA and protein expression in PBMC/serum at 24 hours. Status: unknown.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02364986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364986.